3.63

0.00% 0.00

Proqr Therapeutics N V (PRQR)

Overview News Price History Option Chain Discussions Forecast

Proqr Therapeutics N V stock is traded at $3.63, with a volume of 153.87K. It is up +0.00% in the last 24 hours and up +86.15% over the past month. ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Previous Close:

$3.63

Open:

$3.7

24h Volume:

153.87K

Relative Volume:

0.12

Market Cap:

$300.11M

Revenue:

$7.05M

Net Income/Loss:

$-30.43M

P/E Ratio:

-4.9502

EPS:

-0.7333

Net Cash Flow:

$21.84M

1W Performance:

+5.22%

1M Performance:

+86.15%

6M Performance:

+80.60%

1Y Performance:

+200.00%

1-Day Range:

$3.4901

$3.75

1-Week Range:

$3.37

$3.80

52-Week Range:

$1.18

$4.62

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name

Proqr Therapeutics N V

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

Address

Employee

157

Twitter

@proqr

Next Earnings Date

2024-08-05

Latest SEC Filings

PRQR's Discussions on Twitter

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-30-23	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Dec-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-14-22	Downgrade	Citigroup	Buy → Neutral
Feb-11-22	Downgrade	Raymond James	Strong Buy → Mkt Perform
Feb-11-22	Downgrade	Stifel	Buy → Hold
Feb-01-22	Initiated	Raymond James	Strong Buy
May-03-21	Initiated	Stifel	Buy
Mar-25-21	Reiterated	Citigroup	Buy
Nov-03-20	Resumed	Cantor Fitzgerald	Overweight
Mar-12-19	Reiterated	Chardan Capital Markets	Buy
Dec-19-18	Initiated	RBC Capital Mkts	Outperform
Nov-15-18	Initiated	Citigroup	Buy
Sep-19-18	Initiated	Evercore ISI	Outperform
Sep-26-17	Reiterated	JMP Securities	Mkt Outperform
Jun-20-16	Initiated	Chardan Capital Markets	Neutral
Oct-15-14	Initiated	Deutsche Bank	Buy
Oct-13-14	Initiated	H.C. Wainwright	Buy

View All

Proqr Therapeutics N V Stock (PRQR) Latest News

Oct 30, 2024

Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN

Oct 30, 2024

Oct 29, 2024

ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow

Oct 29, 2024

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat

Oct 29, 2024

Oct 26, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire

Oct 26, 2024

Oct 25, 2024

ProQR Announces Major Share Offering Agreement - TipRanks

Oct 25, 2024

Oct 23, 2024

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St

Oct 23, 2024

ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM

Oct 23, 2024

Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com

Oct 23, 2024

ProQR launches public offering to fund RNA therapy research - Investing.com India

Oct 23, 2024

Oct 22, 2024

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan

Oct 22, 2024

ProQR Therapeutics announces public offering of ordinary shares - MSN

Oct 22, 2024

ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK

Oct 22, 2024

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance

Oct 20, 2024

Oct 16, 2024

RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance

Oct 16, 2024

RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg

Oct 16, 2024

Oct 14, 2024

Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online

Oct 14, 2024

Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times

Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.

Oct 07, 2024

Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World

Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 05, 2024

Oct 04, 2024

Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Oct 04, 2024

Oct 02, 2024

Best Momentum Stocks to Buy for October 2nd - Yahoo Finance

Oct 02, 2024

Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India

Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat

Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World

Sep 27, 2024

Sep 26, 2024